293,576 Shares in Alpha Teknova, Inc. $TKNO Purchased by Royce & Associates LP

Royce & Associates LP bought a new stake in Alpha Teknova, Inc. (NASDAQ:TKNO) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 293,576 shares of the company’s stock, valued at approximately $1,116,000. Royce & Associates LP owned 0.55% of Alpha Teknova as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its holdings in shares of Alpha Teknova by 68.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 90,595 shares of the company’s stock worth $470,000 after purchasing an additional 36,763 shares during the last quarter. Geode Capital Management LLC grew its stake in Alpha Teknova by 64.4% during the 2nd quarter. Geode Capital Management LLC now owns 298,850 shares of the company’s stock worth $1,468,000 after buying an additional 117,016 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Alpha Teknova by 123.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,163 shares of the company’s stock worth $40,000 after buying an additional 4,504 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in Alpha Teknova in the second quarter worth $96,000. Finally, Marshall Wace LLP increased its position in Alpha Teknova by 83.0% in the second quarter. Marshall Wace LLP now owns 90,032 shares of the company’s stock worth $442,000 after buying an additional 40,825 shares during the period. 13.81% of the stock is owned by institutional investors.

Alpha Teknova Price Performance

TKNO opened at $5.40 on Monday. The stock’s 50 day moving average price is $3.35 and its 200 day moving average price is $3.44. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.59 and a quick ratio of 3.60. The stock has a market cap of $289.49 million, a P/E ratio of -16.88 and a beta of 0.62. Alpha Teknova, Inc. has a 12 month low of $1.91 and a 12 month high of $6.68.

Alpha Teknova (NASDAQ:TKNO) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The company had revenue of $11.08 million during the quarter, compared to analysts’ expectations of $10.23 million. Alpha Teknova had a negative return on equity of 24.32% and a negative net margin of 41.07%.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Teknova in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $8.00.

Insider Transactions at Alpha Teknova

In related news, CEO Stephen Gunstream bought 26,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was purchased at an average price of $2.15 per share, for a total transaction of $55,900.00. Following the transaction, the chief executive officer directly owned 269,497 shares of the company’s stock, valued at approximately $579,418.55. This represents a 10.68% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 12.50% of the stock is owned by corporate insiders.

Alpha Teknova Company Profile

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.